Is Retatrutide affected by genetics?
Yes. Its active ingredient has published pharmacogenetic guidance for a gene that varies between people.
Retatrutide is affected by pharmacogenetics through the GIPR and GLP1R genes. Your genotype for these genes can change how well Retatrutide works for you or how well you tolerate it. The strongest evidence level on this page is Weak, from the published guidelines shown below.
What's in Retatrutide
Retatrutide Affected by GIPR, GLP1R
Affected by GIPR, GLP1R. Guidance from Gene2Rx, weak evidence.
Read the full retatrutide genetics guideHow might your genetics affect Retatrutide?
A GLP1R variant is associated with how much weight people lose, and a GIPR variant with nausea and vomiting risk on tirzepatide. Our GLP-1 guide explains what each one means.
Read the GLP-1 genetics guideRetatrutide phenotype recommendations
Published guidance from Gene2Rx on how retatrutide should be dosed or substituted based on your GLP1R, GIPR phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
| Typical ResponseGLP1R | Your genes point to a typical response to this drug, with average weight loss and side effects. | Gene2Rx Standard dosing and titration are expected to produce an average response. |
Weak |
| Enhanced Response (heterozygous)GLP1R | You may lose a little more weight on this drug than average. Your chance of nausea or vomiting is also slightly higher. | Gene2Rx Use standard dosing. Counsel on the likelihood of somewhat greater weight loss and slightly higher GI side-effect risk; consider slower titration if early side effects emerge. |
Weak |
| Enhanced Response (homozygous)GLP1R | You are likely to lose more weight on this drug than average. Your chance of nausea or vomiting is also higher. | Gene2Rx Use standard dosing. Counsel on the likelihood of greater weight loss and higher GI side-effect risk; consider a slower titration schedule to mitigate side effects. |
Weak |
| IndeterminateGLP1R | We couldn't read your GLP1R gene from your data, so we can't tailor advice for this drug. | Gene2Rx Use standard dosing and titration. Monitor response. |
Not rated |
| Not availableGLP1R | We do not have a GLP1R result for you, so we cannot personalize guidance for retatrutide. | Gene2Rx Use standard dosing and titration. Monitor response. |
Not rated |
| Normal FunctionGIPR | Your GIPR gene gives you a typical chance of stomach side effects on this drug. | Gene2Rx Standard dosing and titration. No specific precautions based on GIPR genotype. |
Weak |
| Decreased FunctionGIPR | You may have a somewhat higher chance of nausea or vomiting on retatrutide. This is extrapolated from tirzepatide studies. If side effects become a problem, semaglutide is not affected by this variant. | Gene2Rx Consider a slower dose-escalation schedule for retatrutide. If side effects are intolerable, a GLP1R-only agonist such as semaglutide is unaffected by this variant and may be an alternative. |
Weak |
| Poor FunctionGIPR | You may have a notably higher chance of nausea or vomiting on retatrutide. This is extrapolated from tirzepatide studies. Semaglutide is not affected by this variant and may be better tolerated. | Gene2Rx Consider slower dose escalation for retatrutide, or consider a GLP1R-only agonist such as semaglutide as an alternative (unaffected by this variant). |
Weak |
| IndeterminateGIPR | We couldn't read your GIPR gene, so we can't tell your chance of nausea on this drug. | Gene2Rx Use standard dosing and titration for retatrutide. Monitor for GI side effects. |
Not rated |
| Not availableGIPR | We don't have a GIPR result for you, so we can't tell your chance of nausea on this drug. | Gene2Rx Use standard dosing and titration for retatrutide. Monitor for GI side effects. |
Not rated |
Source: Gene2Rx
The genes behind the guidance
GIPR Gastric Inhibitory Polypeptide Receptor
GIPR is the receptor for GIP, the second incretin hormone. It is the target of the GIP arm of tirzepatide and retatrutide. The Glu354Gln variant (rs1800437) lowers GIPR function, and carriers are more likely to get moderate-to-severe nausea and vomiting on GIP-active drugs. The variant doesn't matter for GLP-1-only drugs like semaglutide.
If someone is struggling with nausea on tirzepatide and carries the Gln354 variant, switching to a GLP-1-only drug often fixes it, since GIPR isn't part of the picture for those drugs.
See all drugs affected by GIPRGLP1R Glucagon-Like Peptide-1 Receptor
GLP1R is the cell-surface receptor that GLP-1 drugs like semaglutide and tirzepatide bind to. A common variant (rs10305420, Pro7Leu) changes how efficiently the receptor gets made and shipped to the cell surface. Leu7 carriers tend to lose a bit more weight on GLP-1 drugs, but they also get more nausea and vomiting.
About 64% of people of European ancestry carry at least one Leu7 allele, and the allele is less common in other groups (28% Admixed American, 16% East Asian, 7% African). The association was measured most precisely in people of European ancestry. The variant doesn't decide whether a GLP-1 drug will work for someone. It changes how strong the response is and shifts the side-effect profile.
See all drugs affected by GLP1RBrowse the full drug class: Weight management (GLP-1 agonists).
Find out how your genetics affect Retatrutide
Informational only, not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.